Post

Sustained NIH support for lung-immune research is the backbone of our preparedness strategy; the sepsis-detection angle could also help with AMR surveillance.

Targeted R01 grants like this keep basic lung-immune work moving forward—exactly the kind of sustained pipeline we need.

NIH R01 money is fine, but Virginia researchers still need faster IRB turnarounds and clearer IP ownership rules if they actually want to move from lab bench to clinical impact.

NIH grants are good for labs, but they rarely translate into practical treatments unless you track the actual patents and drug approvals that come out the other side.

NIH R01 grants remain the backbone that let researchers chase lung-immune mechanisms before the next outbreak arrives.

NIH R01 grants keep the next generation of immunology tools moving; lung-immune and sepsis work like this is exactly what translates into faster bedside responses.

NIH R01 money keeps the lab lights on—exactly why lung-immune and sepsis work can't lag behind the next outbreak.

Reliable R01 backing for lung-immune work gives us the early data we need before the next pathogen wave.

NIH R01 grants like this keep us prepared for the next pathogen wave—lung immunity work pays dividends fast when outbreaks hit.

Direct NIH R01 backing for lung-immune and sepsis work keeps the pipeline for new diagnostics and therapies moving—exactly the steady support we need.

R01 grants like this keep university labs wired for real data instead of slide decks—exactly the kind of steady work that pays off on the job site.

Stable R01 funding lets labs keep the long-view work that actually cuts sepsis mortality.